Gubra A/S
CSE:GUBRA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
114
726
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gubra A/S
Cash Equivalents
Gubra A/S
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Gubra A/S
CSE:GUBRA
|
Cash Equivalents
kr53.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Chemometec A/S
CSE:CHEMM
|
Cash Equivalents
kr296.1m
|
CAGR 3-Years
25%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
Gubra A/S
Glance View
Gubra ApS operates as biotechnology company. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The firm's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.
See Also
What is Gubra A/S's Cash Equivalents?
Cash Equivalents
53.4m
DKK
Based on the financial report for Dec 31, 2023, Gubra A/S's Cash Equivalents amounts to 53.4m DKK.
What is Gubra A/S's Cash Equivalents growth rate?
Cash Equivalents CAGR 3Y
-7%
Over the last year, the Cash Equivalents growth was -26%. The average annual Cash Equivalents growth rates for Gubra A/S have been -7% over the past three years .
You don't have any saved screeners yet
